Cyclacel Pharmaceuticals (NASDAQ:BGMS) Trading Down 0.9% – Should You Sell?

Shares of Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) traded down 0.9% during mid-day trading on Thursday . The company traded as low as $0.98 and last traded at $0.9809. 36,781 shares were traded during trading, a decline of 79% from the average session volume of 176,564 shares. The stock had previously closed at $0.9903.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Wall Street Zen raised Cyclacel Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, November 19th. Weiss Ratings restated a “sell (e+)” rating on shares of Cyclacel Pharmaceuticals in a research note on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

Cyclacel Pharmaceuticals Trading Down 0.9%

The business’s fifty day moving average is $1.35. The stock has a market capitalization of $4.81 million, a PE ratio of -0.01 and a beta of -0.45.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing small-molecule therapies that target the cell cycle and related regulatory pathways for the treatment of cancer and other proliferative diseases. The company’s research and development efforts center on kinase and cell-cycle inhibitors designed to disrupt tumor growth and induce cancer cell death. Cyclacel advances programs through preclinical development and clinical trials with the aim of delivering new therapeutic options for patients with solid tumors and hematologic malignancies.

Key activities at Cyclacel include in-house drug discovery, translational research, and the clinical development of lead candidate molecules.